-
Product Insights
NewMyelofibrosis – Drugs In Development, 2024
Empower your strategies with our Myelofibrosis – Drugs In Development, 2024 report and make more profitable business decisions. Myelofibrosis is a rare bone marrow disorder where abnormal cells cause fibrous tissue buildup, impairing blood cell production. It's a type of myeloproliferative neoplasm, leading to an enlarged spleen, anemia, fatigue, and increased infection risk. JAK2, MPL, or CALR mutations often underlie this condition. Diagnosis involves blood tests, bone marrow biopsy, and imaging. Treatment aims to manage symptoms and might involve medications, blood...
-
Product Insights
NewNatural Killer Cell Lymphomas – Drugs In Development, 2024
Empower your strategies with our Natural Killer Cell Lymphomas – Drugs In Development, 2024 report and make more profitable business decisions. Natural killer (NK) cell lymphomas are a rare and aggressive type of lymphoma arising from a subset of white blood cells called natural killer cells, which are part of the body's immune system. These lymphomas can affect various organs and tissues in the body. NK cell lymphomas are categorized into two main types. Extranodal NK/T-cell lymphoma, nasal type (ENKTL) is...
-
Product Insights
NewChronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Drugs In Development, 2024
Empower your strategies with our Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Drugs In Development, 2024 report and make more profitable business decisions. Chronic myeloid leukemia (CML), also known as chronic myelocytic leukemia, is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. Risk factors for CML include high-dose radiation, age, and gender. Symptoms include weakness, fatigue, night sweats, weight loss, fever, bone pain, an enlarged spleen, and pain or a...
-
Product Insights
NewGraft Versus Host Disease (GVHD) – Drugs In Development, 2024
Empower your strategies with our Graft Versus Host Disease (GVHD) – Drugs In Development, 2024 report and make more profitable business decisions. Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms include abdominal pain or cramps; nausea, vomiting, and diarrhea; dry or irritated eyes; jaundice; shortness of breath; vaginal dryness; and weight loss. Treatment includes immunosuppressants. The Graft Versus Host...
-
Product Insights
NewBone Marrow Transplant Rejection – Drugs In Development, 2024
Empower your strategies with our Bone Marrow Transplant Rejection – Drugs In Development, 2024 report and make more profitable business decisions. Bone marrow transplant rejection is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient's body. Symptoms include chest pain, chills, drop in blood pressure, fever, flushing, funny taste in the mouth, headache, hives, nausea, pain, and shortness of breath. Treatment includes immunosuppressive drugs. The Bone Marrow Transplant...
-
Product Insights
NewB-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) – Drugs In Development, 2024
Empower your strategies with our B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) – Drugs In Development, 2024 report and make more profitable business decisions. B-cell acute lymphocytic leukemia (B-Cell ALL), also known as B-cell acute lymphoblastic leukemia, is a type of blood cancer that originates in the bone marrow and affects B-cell lymphocytes, a type of white blood cell. In B-cell ALL, these immature B cells undergo malignant transformation, leading to the rapid production of abnormal lymphoblasts. These abnormal cells...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zatolmilast in Fragile X Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zatolmilast in Fragile X Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Zatolmilast in Fragile X SyndromeDrug Details:BPN-14770 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FOL-100 in Androgenic Alopecia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.FOL-100 in Androgenic AlopeciaDrug Details:FOL-100 is under development for the treatment of male androgenetic alopecia. The...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Camidanlumab Tesirine in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Camidanlumab Tesirine in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Camidanlumab tesirine in Hodgkin Lymphoma (B-Cell Hodgkin...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Camidanlumab Tesirine in Myelodysplastic Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Camidanlumab Tesirine in Myelodysplastic Syndrome report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Camidanlumab tesirine in Myelodysplastic Syndrome Drug Details: Camidanlumab tesirine is...